Abstract: A process for selecting DNA sequences that are optimal for the production of polypeptides in hosts transformed with those DNA sequences. These DNA sequences, which code for a variety of human and animal proteins, permit the high level expression of those products in host cells. In the preferred embodiment of this invention, DNA sequences optimal for the production of human somatomedin C are selected and employed to express that growth enhancing factor.

Abstract: A method for introducing a biological substance into a target which utilizes particles having a substantially pure carbonaceous surface to which is associated a biological substance wherein the particles are sufficiently small to penetrate the target without killing the target is described.

Abstract: A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant.Additionally described is a pharmaceutical containing a transglutaminase and a plasminogen activator inhibitor.

Abstract: Positive-negative selector (PNS) vectors are provided for modifying a target DNA sequence contained in the genome of a target cell capable of homologous recombination. The vector comprises a first DNA sequence which contains at least one sequence portion which is substantially homologous to a portion of a first region of a target DNA sequence. The vector also includes a second DNA sequence containing at least one sequence portion which is substantially homologous to another portion of a second region of a target DNA sequence. A third DNA sequence is positioned between the first and second DNA sequences and encodes a positive selection marker which when expressed is functional in the target cell in which the vector is used. A fourth DNA sequence encoding a negative selection marker, also functional in the target cell, is positioned 5' to the first or 3' to the second DNA sequence and is substantially incapable of homologous recombination with the target DNA sequence.

Abstract: Fibroblasts transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced fibroblasts. Such fibroblasts are useful in delivering the encoded polypeptide or protein, such as an enzyme, a hormone or a drug, to an individual who has had a graft or implant of the transduced cells.

Abstract: The nucleotide sequence of a DNA coding for highly thermophilic cytochrome C-552, a plasmid containing said sequence, a host cell transformed with said plasmid and a process for the production of C-552 comprising culturing said host.

Abstract: A process for the activation of t-PA or IgG after expression in prokaryotes is described. The process includes cell digestion, solubilization under denaturing and reducing conditions and activation under oxidizing conditions in the presence of GSH/GSSG.

Abstract: Packaging cell lines useful for the generation of helper-free recombinant retroviruses with amphotropic or ecotropic host ranges, methods of constructing such packaging cell lines and methods of using the recombinant retroviruses to introduce DNA of interest into eukaryotic cells, both in vitro and in vivo.

Abstract: L-tryptophan is produced by constructing a recombinant DNA composed of a vector DNA and DNA fragments bearing all of genetic information relating to the synthesis of DS, AS, PRT, PRAI, InGPS, TS and PGDH, introducing the recombinant DNA into a microorganism belonging to the genus Corynebacterium or Brevibacterium, culturing the microorganism in a medium, and recovering L-tryptophan accumulated in the culture.

Abstract: This invention relates to oligonucleotides having at least one nucleotide that is substituted at the 4' position of the sugar moiety with a substituent other than hydrogen. These oligonucleotides are useful in hybridization assays and as therapeutic agents.

Abstract: This invention relates to a color controlled disinfecting peroxide cold sterilization composition employing an iodide salt and to a method for controlling the formation and duration of color when such composition is combined with water.

Abstract: The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Parkinson disease and Alzheimer disease are due to lack of a disorder-specific neurotrophic hormone or factor. Diagnosis is accomplished by assaying factors specific for a particular neuronal network or system; for example, dopamine neutotrophic hormones from striatum or caudate-putamen in the nigrostriatal dopaminergic neural system are used to diagnose and treat parkinsonism. With tissue culture, the presence or absence of spacific neurotrophic factos can be assessed in ALS, parkinsonism, and Alzheimer disease. If there is a deficiency, extracted and purified neurotrophic factors specific to the particular neuronal network or system can be injected into a patient having ALS, Alzheimer disease or parkinsonism for treatment of the disease.

Abstract: A method is provided for inhibiting tumor growth by administering to a subject an effective tumor-inhibiting amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 2 to 4 grams/kilogram bodyweight per day.

Abstract: Immune serum globulins (ISG) can be made substantially free of infectious retroviruses by storing the ISG in a liquid state at conditions of pH, temperature and time sufficient to inactivate substantially all infectious retroviruses. Preferred inactivation methods involve use of either of two specified storage conditions: (1) at a pH equal to or less than about 4.25 at a temperature of about 27.degree. C. for at least 3 days, or (2) at a pH equal to or less than about 6.8 at a temperature of about 45.degree. C. for at least about 8 hours.

Abstract: Methods are disclosed for enhancing the healing of a variety of wounds in horses. The methods generally comprise administering to the wound a therapeutically effective amount of a composition comprising GHL:Cu or a derivative thereof in combination with a physiologically acceptable carrier or diluent.

Abstract: The use of TNF in the treatment of disorders which are accompanied by reduced leucocyte and/or marrow cell counts or functions is described.

Abstract: The body composition of poultry is improved by a hormonal strategy that involves either:(1). increasing plasma levels of thyroid hormone by about 2- to 3-fold during the finishing phase (e.g., for chickens, 3 to 6 or 7 weeks-of-age) by providing feed containing 0.1 to 1 ppm of metabolically-active thyroid hormone of the formula: ##STR1## wherein R1 is the residue of a carboxylic acid such as an alpha-amino acid or an aliphatic carboxylic acid, e.g. L-alanine, D-alanine, acetic acid, or propionic acidR3 is iodine (I)R5 is iodine (I) or hydrogen (H)R3' is iodine (I) or the residue of an aliphatic carboxylic acid such as butyric acid, or propionic acidR5' is iodine (I) or hydrogen (H)R4' is hydroxy (OH)(2). increasing plasma levels of metabolically-active thyroid hormone by 2- to 3-fold and increasing plasma levels of growth hormone or glucagon by 2- to 10-fold for 15 to 30% of each day with any suitable method during the finishing phase of poultry growth.

Abstract: A lyophilized pharmaceutical formulation of tissue plasminogen activator and a process for its preparation by vaccum drying a frozen aqueous solution of thereof, in which the pH is from 2 to 5.

Abstract: The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Parkinson disease and Alzheimer disease are due to lack of disorder-specific neurotrophic factors. Specific neurotrophic factors of .about.20-22 kD and .about.16-18 kD have been isolated from rat and human skeletal motor neurons, respectively, and purified. With tissue culture, the presence or absence of the specific neurotrophic factors provided herein can be assessed in ALS. If there is a deficiency, extracted and purified neurotrophic factors specific to the motor neuronal network or system can be administered to ALS-affected individuals.

Abstract: A lipid powder having a cross-linked coating thereon comprises a core lipid powder and a water-soluble coating agent coating the core lipid powder. The water-soluble coating agent contains cross-linked protein. A process for preparing lipid powders each having a cross-linked coating thereon comprises the steps of emulsifying lipid and a water-soluble coating agent containing protein to obtain an emulsion, adding a cross-linking agent for the protein the the emulsion to thereby cross-link the protein, atomizing and drying the emulsion containing the cross-linked protein to terminate the cross-linking reaction and to obtain lipid powders each coated with the water-soluble coating agent, and cooling the coated lipid powders.